Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 15:13:969183.
doi: 10.3389/fphar.2022.969183. eCollection 2022.

The microtubule cytoskeleton: An old validated target for novel therapeutic drugs

Affiliations
Review

The microtubule cytoskeleton: An old validated target for novel therapeutic drugs

Laurence Lafanechère. Front Pharmacol. .

Abstract

Compounds targeting microtubules are widely used in cancer therapy with a proven efficacy. However, because they also target non-cancerous cells, their administration leads to numerous adverse effects. With the advancement of knowledge on the structure of tubulin, the regulation of microtubule dynamics and their deregulation in pathological processes, new therapeutic strategies are emerging, both for the treatment of cancer and for other diseases, such as neuronal or even heart diseases and parasite infections. In addition, a better understanding of the mechanism of action of well-known drugs such as colchicine or certain kinase inhibitors contributes to the development of these new therapeutic approaches. Nowadays, chemists and biologists are working jointly to select drugs which target the microtubule cytoskeleton and have improved properties. On the basis of a few examples this review attempts to depict the panorama of these recent advances.

Keywords: drug development; microtubule regulations; microtubules; targeted therapies; tubulin; tubulin post-translational modifications; tubulin-binding drugs.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abbas A. J., Ibrahim M. F., Saifo M. S. (2021). Antibody-drug conjugates used in breast cancers. J. Oncol. 2021, 9927433. 10.1155/2021/9927433 - DOI - PMC - PubMed
    1. Adamopoulos A., Landskron L., Heidebrecht T., Tsakou F., Bleijerveld O. B., Altelaar M., et al. (2019). Crystal structure of the tubulin tyrosine carboxypeptidase complex VASH1–SVBP. Nat. Struct. Mol. Biol. 26, 567–570. 10.1038/s41594-019-0254-6 - DOI - PubMed
    1. Ahmed T., Shea K., Masters J. R. W., Jones G. E., Wells C. M. (2008). A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell. Signal. 20, 1320–1328. 10.1016/j.cellsig.2008.02.021 - DOI - PubMed
    1. Aillaud C., Bosc C., Peris L., Bosson A., Heemeryck P., Dijk J. Van, et al. (2017). Vasohibins/SVBP are tubulin carboxypeptidases (TCPs) that regulate neuron differentiation. Science 358, 1448–1453. 10.1126/science.aao4165 - DOI - PubMed
    1. Akhmanova A., Hoogenraad C. C. (2005). Microtubule plus-end-tracking proteins: Mechanisms and functions. Curr. Opin. Cell. Biol. 17, 47–54. 10.1016/j.ceb.2004.11.001 - DOI - PubMed

LinkOut - more resources